Friends of Cancer Research has launched a collaboration that aims to address concerns about the lack of consistency in determining homologous recombination deficiency—HRD—status, its prognostic value, and its use as a predictive biomarker.
The Biden administration has left NIH in a weakened state, intensifying politicization of science on Capitol Hill and eroding the bipartisan support the government’s premier biomedical research agency has traditionally enjoyed.
